296 related articles for article (PubMed ID: 34170207)
1. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
2. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
4. Report of consensus panel 1 from the 11
Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
[TBL] [Abstract][Full Text] [Related]
5. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
6. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
Kyle RA; Ansell SM; Kapoor P
Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report.
Kikukawa Y; Yamamura-Fujimoto A; Endo S; Miyagawa E; Kawano Y; Ueno S; Mitsuya H; Hata H; Okuno Y
J Clin Exp Hematop; 2015; 55(2):113-9. PubMed ID: 26490525
[TBL] [Abstract][Full Text] [Related]
10. Reducing treatment toxicity in Waldenström macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Expert Opin Drug Saf; 2021 Jun; 20(6):669-676. PubMed ID: 33645373
[No Abstract] [Full Text] [Related]
11. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
13. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
14. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
15. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
17. Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.
Awad AK; Elbadawy MA; Boury M; Rivera A; Motawea K; Shah J; Parnia S; Varney J
J Egypt Natl Canc Inst; 2022 Mar; 34(1):10. PubMed ID: 35253074
[TBL] [Abstract][Full Text] [Related]
18. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
Dimopoulos MA; Kastritis E; Ghobrial IM
Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
[TBL] [Abstract][Full Text] [Related]
19. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]